Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy

  • Authors:
    • Xiao-Qin Tian
    • Li-Min Zhao
    • Jia-Pu Ge
    • Yan Zhang
    • Yan-Cheng Xu
  • View Affiliations

  • Published online on: November 26, 2013     https://doi.org/10.3892/etm.2013.1426
  • Pages: 411-416
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Improving the early prediction and detection of diabetic nephropathy (DN) remains a great challenge in disease management. The aim of this study was to evaluate the early detection power of urinary vitamin D‑binding protein (VDBP) for the diagnosis of DN. Urine samples were obtained from 45 healthy volunteers and 105 diabetic patients with normoalbuminuria (DM group), microalbuminuria (DN1 group) and macroalbuminuria (DN2 group) (n=35 per group). The VDBP expression patterns in urine from patients and controls were quantified by western blot analysis. The excretion levels of urinary VDBP were quantified with enzyme-linked immunosorbent assay. The quantification results were obtained by correcting for creatinine expression and showed that urinary VDBP levels were significantly elevated in the patients of the DN1 and DN2 groups compared with those of the DM group and normal controls (1,011.33±325.30 and 1,406.34±239.66 compared with 466.54±213.63 and 125.48±98.27 ng/mg, respectively) (P<0.001). Receiver operating characteristic analysis of urinary VDBP levels for the diagnosis of DN rendered an optimum cut-off value of 552.243 ng/mg corresponding to 92.86% sensitivity and 85.00% specificity, which also showed an area under the ROC curve of 0.966. In conclusion, the findings of the present study suggest that urinary VDBP may be a potential biomarker for the early detection and prevention of DN. Further studies are required to examine the pathogenic mechanisms of elevated VDBP levels and their role in the diagnosis of DN.

Introduction

Diabetes is the fifth leading cause of mortality in the United States and the world prevalence of diabetes is increasing at an alarming rate with >1 million new patients per year diagnosed in the United States (1,2). Furthermore, diabetes results in substantial mortality and morbidity (3). Although the current methods of diagnosis and treatment of diabetes have improved, the long-term prognosis remains poor (4). In addition, there are few effective preventive measures against its development. Epidemiological data suggested that disease prevalence is likely to continue to increase globally without effective prevention and control (5).

Diabetic nephropathy (DN) is one of the most common complications, which results in chronic kidney disease in diabetic patients. It is also one of the causes of increased cardiovascular mortality (4). However, a considerable amount of significant diabetic renal structural injury may occur in absolute clinical silence, which renders diagnosis difficult. Currently, routine kidney biopsy for DN is not permitted in clinical practice, as the procedure is invasive. Microalbuminuria is considered as the best available, non-invasive marker for DN risk, but certain studies have shown it to have inadequate specificity and sensitivity (6,7). Thus, additional studies into novel invasive risk markers are required, and feasible measures for the diagnosis of DN prior to advanced renal dysfunction are considered to be of clinical importance with public health implications.

Vitamin D-binding protein (VDBP), also known as gc-globulin, bonds and transports vitamin D throughout the body. It also is important in the actin-scavenger system, ensuing immune responses and inflammation processes (8). Clinically, it has been demonstrated that exaggerated excretion of urinary VDBP is associated with tubular dysfunction (9). Therefore, it was hypothesized that the loss of urinary VDBP is likely to be elevated in diabetic patients and particularly accentuated in those patients with DN. In the present study, the early detection and predictive value of urinary VDBP for DN was assessed.

Materials and methods

Patient selection and urine specimen collection

In this study, 105 Chinese Han individuals with diabetes and 45 healthy volunteers (control group) were recruited from the Traditional Chinese Medicine Hospital attached to Xinjiang Medical University (Urumqi, China) from June 2012 to January 2013. The patients were divided into three groups according to the value of the urinary albumin:creatinine (Cr) ratio (UACR): DM group without nephropathy and albuminuria (UACR<30 mg/g, n=35), early DN group (DN1) with microalbuminuria (30≤UACR<300 mg/g, n=35) and overt DN group (DN2) with macroalbuminuria (UACR≥300 mg/g, n=35). All study subjects were >18 years old and blood pressure was maintained at 140/90 mmHg by the use of angiotensin-receptor blockers or angiotensin-converting enzyme inhibitors. Moreover, blood glucose was controlled with human insulin. Within the 2 weeks prior to urine collection, patients did not receive additional medicine and the controls did not receive any medication. Patients were excluded if they showed the following: Liver diseases, autoimmune diseases, inflammatory diseases, pregnancy, urinary system disorders, tumors, infections, decompensated heart failure, cardiovascular events within 6 months, hematological diseases and known renal diseases other than DN. Studies were approved by the local ethics committee of the Traditional Chinese Medicine Hospital attached to Xinjiang Medical University (Urumqi, China). All patients were informed about the purpose of the study and gave their written consent.

Urine specimen collection

The second voided clean-catch urine samples from all patients were collected early in the morning. Each urine sample (20 ml) was directly collected into a sterile plastic tube and then immediately centrifuged at 2,500 × g for 10 min at 4°C to remove cell debris and particulate matter. The supernatant was stored at −80°C for further analysis. Repeated freeze-thaw cycles were avoided. Clinical data of all patients were also collected.

Western blot analysis

The stored supernatant was used for western blot analysis after measuring the protein concentrations. The urine samples were first thawed on ice, adding 1 mmol/l phenylmethanesulfonyl fluoride (Sigma, St. Louis, MO, USA), and then centrifuged using Centricon Plus-20, 10,000 MWCO devices (Millipore, Bedford, MA, USA). Then the concentrated urinary proteins were precipitated using a ReadyPrep 2-D clean up kit (GE Healthcare, Piscataway, NJ, USA) to remove other interfering components according to the manufacturer’s instructions The concentrations of urinary proteins were determined by using the Bradford protein assay kits (GE Healthcare). The samples examined were from patients from the DM, DN1, DN2 and control groups (n=8 per group). A total of 20 μg prepared proteins isolated from the urine samples were electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide gel. The proteins were then transferred onto polyvinylidene fluoride membranes (Immobilon P; Millipore, Billerica, MA, USA). The membranes were blocked for 1 h at 37°C in a solution of TBS containing 5% non-fat milk powder and 0.1% Tween-20 (TBS-T) and then incubated overnight at 4°C with rabbit monoclonal primary antibody against human VDBP (diluted 1:1,000; Abcam, Cambridge, UK). Membranes were washed three times for 10 min in TBS-T and then incubated with horseradish peroxidase horseradish-coupled goat anti-rabbit IgG (Beijing Zhongshan Biotechnology Co. Ltd., Beijing, China) at a 1:500 dilution at room temperature for 1 h. The proteins were detected using an enhanced chemiluminescence detection system (ECL-Direct systems RPN3000; Pierce Biotechnology, Inc., Rockford, IL, USA). Triplicate gel images of identical samples were used for analysis. It was quantified by strip densitometry.

Enzyme-linked immunosorbent assay (ELISA)

All the samples were centrifuged at 3,500 × g for 5 min at 4°C to remove interfering matter prior to ELISA analysis. The concentrations of VDBP in the urine samples were measured with a Human Vitamin D BP Quantikine ELISA kit (DVDBP0; R&D Systems, Minneapolis, MN, USA). The assay was performed according to the instructions recommended by the manufacturer. The standard curve was created using the lyophilized human VDBP standard preparation supplied with the assay. Following the colorimetric reaction, the optical density (OD) readings were converted to concentrations in ng/ml based on quantification of the OD at 450 nm using an eight-channel spectrophotometer (Fast model; BD Biosciences, Franklin Lakes, NJ, USA). Measured VDBP levels ranged from 0 to 250 ng/ml. Urine Cr levels were measured at the Department of Clinical Laboratory, Traditional Chinese Medicine Hospital attached to Xinjiang Medical University (Urumqi, China). The levels of VDBP were normalized according to urine Cr concentrations so as to avoid the influence of urine volume and presented as VDBP:Cr ratio (VDBP-Cr; ng/mg of Cr) (10). Every sample was tested in duplicate.

Statistical analysis

All data were collected and presented as the mean ± standard deviation. The differences among groups were compared with Student’s t-test between two groups or one-way analysis of variance for three groups. Receiving operating curve (ROC) analyses were used to explore the diagnostic performance of urinary VDBP:Cr over a range of possible clinical results on the basis of estimating the sensitivity versus its false-positive rate at optimal cut-offs (10,11). The best statistical cut-off value of VDBP:Cr was defined, which means the point at which the sum of sensitivity and specificity is more than that at other points. Pearson’s correlation coefficient analysis was employed to explore the association between the VDBP:Cr and the clinical features of patients. Multivariate logistical regression analysis was utilized to determine the risk factors for DN. All statistical analyses were performed with SPSS software, version 13.0 (SPSS, Chicago, IL, USA). All tests were two tailed and P<0.05 was considered to indicate a statistically significant difference.

Results

Clinical characteristics of patients

The clinical characteristics of all patients are shown in Table I. Samples from 35 DM, 35 DN1 and 35 DN2 patients and 45 controls were collected for ELISA analysis. Analysis of the patient data indicated that there were no statistically significant differences in the majority of clinical characteristics (e.g. age, gender, smoking and duration of diabetes) among the four groups. However, significant differences were identified in serum Cr, UACR and systolic blood pressure between certain groups (serum-Cr: DN2 vs. control P=0.025, DN2 vs. DM: P=0.012 DN2 vs. DN1: P=0.034, UACR-DN1 vs. control: P<0.001, DN1 vs. DM: P<0.001; DN2 vs. control P<0.001, DN2 vs. DM: P<0.001, DN2 vs. DN1: P<0.001; systolic blood pressure-DN1 vs. control: P=0.021, DN2 vs. control: P=0.014). Additionally, as the patients in each experimental group had taken similar medications, the effect of taking medicine on the results was ignored.

Table I

Clinical and demographic data for the patients subjected to ELISA analysis.

Table I

Clinical and demographic data for the patients subjected to ELISA analysis.

CharacteristicsControlDM groupDN1 groupDN2 group
Cases (n)45353535
Age (years)60.89±13.9264.63±11.7664.49±11.7864.80±12.98
Gender (n)
 Male31221821
 Female1413174
Smoking (n)
 Yes20141719
 No25211816
Diabetes (n)
 Type 10557
 Type 20303028
Diabetic duration (years)011.43±7.8312.77±8.6511.57±6.45
Systolic BP (mmHg)115±8.32120±9.59134±8.76*143±10.32*
Serum creatinine (μmol/l)99.84±24.2392.43±36.65107.34±46.62142.46±55.10*,**,***
UACR (mg/g)10.52±2.7813.08±4.11134.66±47.2*,** 1603.09±544.60*,**,***
Taking ACEI (n)0121514
Taking ARB (n)0131012
Insulin therapy (n)0353535

{ label (or @symbol) needed for fn[@id='tfn1-etm-07-02-0411'] } Measurement data are presented as the mean ± standard deviation.

* P<0.05 compared with the control group;

** P<0.05 compared with the DM group; and

*** P<0.05 compared with the DN1 group.

{ label (or @symbol) needed for fn[@id='tfn5-etm-07-02-0411'] } DM, UACR<30 mg/g; DN, diabetes nephropathy; DN1, with microalbuminuria 30<UACR<300 mg/g; DN2, with microalbuminuria UACR>300 mg/g; UACR: urinary albumin:creatinine ratio; BP, blood pressure; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; ELISA, enzyme-linked immunosorbent assay.

Analysis of urinary VDBP by western blotting

To verify the expression of urinary VDBP in individual urine samples by western blotting, 32 samples from the DM, DN1, DN2 and control groups (n=8 per group) were randomly selected. The results demonstrated that urinary VDBP levels were significantly upregulated in the DM group compared with that of the control group (Fig. 1). Furthermore, the levels of urinary VDBP were significantly elevated in the DN groups compared with those of the DM and control groups (Fig. 1).

Detection of urinary VDBP expression

To explore the changes of urinary VDBP expression in DN patients, ELISA analysis was conducted on the 150 urine samples from the DM, DN1, DN2 and control groups.

The levels of urinary VDBP were significantly higher in patients than in controls (961.41±542.77 versus 125.48±98.27 ng/mg, P<0.001; Fig. 2A). After division of the patients into groups by UACR, it was indicated that the expression levels of urinary VDBP were significantly higher in the DN1 and DN2 groups than in the DM group (1,011.33±325.30 and 1,406.34±239.66 versus 466.54±213.63 ng/mg, respectively; P<0.001). A significant difference was also observed between the DN2 and DN1 groups (P<0.001; Fig. 2A and Table II).

Table II

Correlation between levels of urinary VDBP and clinical features of diabetic patients.

Table II

Correlation between levels of urinary VDBP and clinical features of diabetic patients.

Clinical featuresNo.Urinary VDBP levels (ng/mg)P-value
Age
 >65 years521009.52±533.270.37
 ≤65 years53914.20±552.91
Gender
 Female441001.44±491.330.52
 Male61932.53±579.32
Hypertension
 With361050.86±426.160.22
 Without69914.74±592.15
Smoking
 Yes501043.62±618.680.14
 No55886.66±456.19
Renal dysfunction
 With381263.15±531.33<0.001
 Without67790.27±473.08
Diabetes
 Type 1181083.46±582.210.30
 Type 287936.15±534.31
Diabetic duration
 >12 years43975.74±543.320.82
 ≤12 years62951.46±546.60
DM group35466.54±213.63<0.001
DN1 group351011.33±325.30
DN2 group351406.34±539.66

[i] DM, UACR<30 mg/g; DN, diabetic nephropathy; DN1, early DN with microalbuminuria (30<UACR<300 mg/g); DN2, overt DN group with macroalbuminuria (UACR>300 mg/g). UACR, urinary albumin:creatinine ratio; VDBP, vitamin D binding protein.

Correlation and multivariate logistical regression analyses

Additional subgroup analyses were performed to clarify the correlation between urinary VDBP levels and clinical characteristics of the patients (Table II). No significant association was observed between the urinary loss of VDBP and the clinical features of DM patients, such as age, gender, smoking, duration of DM and hypertension, with the exception of DN and renal dysfunction. The enhanced excretion levels of urinary VDBP were significantly higher in patients with renal dysfunction than in the patients without dysfunction (1,263.15±531.33 versus 790.27±473.08 ng/mg; P<0.001). Furthermore, higher urinary VDBP concentrations were detected in the DN1 and DN2 groups than in the DM group (P<0.001). The Spearman rank correlation was 0.707, which indicated that the levels of urinary VDBP had a strong positive correlation with the development of DN. Also, multivariate logistical regression analysis was conducted to assess the independent risk factors for DN. The results suggested that serum Cr may be an independent predictor of DN (OR=1.29, 95% confidence interval, 1.02–1.57; P=0.04).

Evaluation of urinary VDBP as a biomarker for DN

Following quantitative analysis of 150 urine samples by ELISA, ROC curves were used to assess the potential utility of urinary VDBP detection in patients with DN. The area under the ROC curve of urine VDBP levels for the diagnosis of DN was 0.966 (95% CI, 0.924–0.989). The analysis rendered an optimum cut-off value of 552.243 ng/mg corresponding to 92.86% sensitivity and 85.00% specificity (Fig. 2B).

Discussion

Improving the early prediction and detection of DN remains a great challenge in disease management (13,14). Improving the predictive ability of testing would greatly benefit the treatment of patients with DN and facilitate the monitoring of the condition. To explore whether urine VDBP levels may be a novel non-invasive biomarker for DN, the results of the present study demonstrated that the expression level of urinary VDBP was highly upregulated in patients with DN. Furthermore, the levels of VDBP were measured in the urine samples from the control, DM and DN groups.

VDBP is a 58-kDa glycoprotein and is present in the serum at a concentration of 300–600 mg/ml (15). It serves as the main carrier protein for vitamin D in the bloodstream. VDBP is important in the bioavailability of active 1,25-dihydroxyvitamin D (1,25(OH)2D) and its precursor 25-hydroxyvitamin D (25OHD) (16,17). The transportation of vitamin D by VDBP is important for the function of a wide variety of tissues and changes in VDBP activity result in the development of a number of diseases (8).

In addition to its transport function, VDBP is the parent molecule of VDBP-maf (macrophage activating factor). VDBP-maf is the product of the selectively deglycosylated form of VDBP and has been demonstrated to be a potent antiangiogenic and antitumorigenic molecule (18). Such functions would greatly benefit the regulation of the growth of cancer cells and protection against certain immune disorders (19). These important and diverse properties of VDBP have been suggested in previous studies with regard to a number of tumor types (20,21). Moreover, VDBP is important in the actin scavenger system and inflammation processes (8). Studies concerning the actions of VDBP in the kidney have received increased attention and have suggested that VDBP is vital in the endocrine biosynthetic process of 1,25(OH)2D within renal proximal tubules; in this process, 25OHD binds to VDBP and the complex is actively recovered from glomerular filtrate through megalin-mediated receptor endocytosis (22,23).

In the present study, following quantitative measurements of 150 urine samples with ELISA, it was identified that the VDBP expression levels were significantly higher in the urine samples from patients with DN than in the urine from the DM and control groups. Furthermore, a strong positive correlation was observed between the urinary VDBP levels and the development of DN. ROC analysis rendered that an optimum cut-off value of urinary VDBP of 552.243 ng/mg corresponding to 92.86% sensitivity and 85.00% specificity is appropriate for detecting DN. On the basis of these analyses, urinary VDBP was indicated to be a potential biomarker for the early detection and prevention of DN.

The reasons underlying the enhanced excretion of urinary VDBP in patients with DN remain unclear. One possible explanation is that elevated urinary VDBP levels may be associated with renal tubular damage in DN patients (24,25). Renal tubular epithelial cell damage becomes increasingly severe as DN develops. In a previous study, increased excretion of urinary VDBP was observed following long-term cadmium exposure, and it was suggested that the marked loss of VDBP in the urine may be linked to renal tubular dysfunction and bone lesions in the inhabitants of cadmium-polluted areas (26). In addition, it has been demonstrated that the presence of vitamin D deficiency or insufficiency in patients with diabetes is independently associated with the development of DN. Moreover, exaggerated urinary excretion of VDBP was observed in patients with Type I diabetes, which contributed mechanistically to vitamin D deficiency in this disease (9,27,28). Therefore, a further possibility for the elevated urinary VDBP levels identified in the present study may be associated with the relatively lower serum vitamin D levels. Further studies are required to clarify the role of VDBP in the pathogenesis of DN.

Clinically, there have been studies on aspects of other diseases, which demonstrated the increased urinary excretion of VDBP. Recently, Mirković et al indicated that the urinary excretion of VDBP may be a novel urinary biomarker of tubulointerstitial damage (29). Cho et al demonstrated that the urinary VDBP loss was significantly elevated in patients with endometriosis than those without. However, the authors suggested that urinary VDBP has limited value as a potential early diagnostic biomarker for endometriosis (10). A study by Zoidakis et al identified that the reduction of VDBP levels in the urine of patients with invasive bladder cancer was significant (30), which is consistent with the findings by Li et al(8). Moreover, Li et al also demonstrated that the expression levels of urinary VDBP were positively associated with the pathological classification of bladder cancer (9). Their results suggested that urinary VDBP may be a potential non-invasive biomarker for the early diagnosis and effective surveillance of bladder cancer (8). In the present study, to the best of our knowledge, it was demonstrated for the first time that increased urinary VDBP levels occurred in patients with DN, and there was a strong positive association between urinary VDBP levels and the development of DN.

An important limitation of the present study regarding the specificity of this biomarker should be considered when urinary VDBP detection is used for early prevention of DN. It has been demonstrated that urinary VDBP levels are closely associated with renal dysfunction. In the present study, urine samples were collected from patients with DN only, but not from patients with additional nephropathies. This may have caused an overestimation of the specificity of VDBP as a biomarker for the detection of DN. Therefore, further studies including a larger sample and analyses from patients with various types of non-diabetic nephropathy are required to clarify this issue.

In conclusion, the current study demonstrated that urinary VDBP levels were significantly elevated in patients with DN. Moreover, a strong positive correlation was observed between the expression level of urinary VDBP and the development of DN. Thus, the findings indicate that urinary VDBP levels are a potential biomarker for the early detection and prevention of DN. Further studies are warranted to examine the pathogenic mechanisms of elevated VDBP and its role in the diagnosis of DN.

References

1 

Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG and Willett WC: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 345:790–797. 2001. View Article : Google Scholar : PubMed/NCBI

2 

Pittas AG, Lau J, Hu FB and Dawson-Hughes B: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 92:2017–2029. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Iso H: Changes in coronary heart disease risk among Japanese. Circulation. 118:2725–2729. 2008. View Article : Google Scholar : PubMed/NCBI

4 

Valmadrid CT, Klein R, Moss SE and Klein BE: The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 160:1093–1100. 2000. View Article : Google Scholar : PubMed/NCBI

5 

Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004.PubMed/NCBI

6 

Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM and Herman WH: Does microalbuminuria predict diabetic nephropathy? Diabetes Care. 24:1560–1566. 2001. View Article : Google Scholar : PubMed/NCBI

7 

Jiang H, Guan G, Zhang R, Liu G, Cheng J, Hou X and Cui Y: Identification of urinary soluble E-cadherin as a novel biomarker for diabetic nephropathy. Diabetes Metab Res Rev. 25:232–241. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Li F, Chen DN, He CW, Zhou Y, Olkkonen VM, He N, Chen W, Wan P, Chen SS, Zhu YT, Lan KJ and Tan WL: Identification of urinary Gc-globulin as a novel biomarker for bladder cancer by two-dimensional fluorescent differential gel electrophoresis (2D-DIGE). J Proteomics. 77:225–236. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Thrailkill KM, Jo CH, Cockrell GE, Moreau CS and Fowlkes JL: Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency? J Clin Endocrinol Metab. 96:142–149. 2011. View Article : Google Scholar : PubMed/NCBI

10 

Cho S, Choi YS, Yim SY, Yang HI, Jeon YE, Lee KE, Kim H, Seo SK and Lee BS: Urinary vitamin D-binding protein is elevated in patients with endometriosis. Hum Reprod. 27:515–522. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 143:29–36. 1982. View Article : Google Scholar : PubMed/NCBI

12 

Jiang H, Guan G, Zhang R, Liu G, Liu H, Hou X and Cheng J: Increased urinary excretion of orosomucoid is a risk predictor of diabetic nephropathy. Nephrology (Carlton). 14:332–337. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Dihazi H and Müller GA: Urinary proteomics: a tool to discover biomarkers of kidney diseases. Expert Rev Proteomics. 4:39–50. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS and Arthur JM: Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol. 18:913–922. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Cooke NE and David EV: Serum vitamin D-binding protein is a third member of the albumin and alpha fetoprotein gene family. J Clin Invest. 76:2420–2424. 1985. View Article : Google Scholar : PubMed/NCBI

16 

Chun RF, Peercy BE, Adams JS and Hewison M: Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. PLoS One. 7:e307732012. View Article : Google Scholar : PubMed/NCBI

17 

Christakos S, Ajibade DV, Dhawan P, Fechner AJ and Mady LJ: Vitamin D: metabolism. Endocrinol Metab Clin North Am. 39:243–253. 2010. View Article : Google Scholar

18 

Yamamoto N and Naraparaju VR: Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats. Cell Immunol. 170:161–167. 1996. View Article : Google Scholar : PubMed/NCBI

19 

Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, Huang B, Pirie-Shepherd S and Fannon M: Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One. 5:e134282010. View Article : Google Scholar

20 

Yamamoto N, Naraparaju VR and Asbell SO: Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 56:2827–2831. 1996.PubMed/NCBI

21 

Yamamoto N, Suyama H, Nakazato H, Yamamoto N and Koga Y: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother. 57:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI and Willnow TE: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 96:507–515. 1999. View Article : Google Scholar : PubMed/NCBI

23 

Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM and Hewison M: Extrarenal expression of 25-hydroxyvitamin D3-1α-hydroxylase. J Clin Endocrinol Metab. 86:888–894. 2001.PubMed/NCBI

24 

Colston K, Williams NJ and Cleeve HJ: Studies on vitamin D binding protein in the nephrotic syndrome. Clin Chem. 31:718–721. 1985.PubMed/NCBI

25 

Vilasi A, Cutillas PR, Maher AD, Zirah SF, Capasso G, Norden AW, Holmes E, Nicholson JK and Unwin RJ: Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol. 293:F456–F467. 2007. View Article : Google Scholar : PubMed/NCBI

26 

Uchida M, Teranishi H, Aoshima K, Katoh T, Kasuya M and Inadera H: Elevated urinary levels of vitamin D-binding protein in the inhabitants of a cadmium polluted area, Jinzu River basin, Japan. Tohoku J Exp Med. 211:269–274. 2007. View Article : Google Scholar : PubMed/NCBI

27 

Svoren BM, Volkening LK, Wood JR and Laffel LM: Significant vitamin D deficiency in youth with type 1 diabetes mellitus. J Pediatr. 154:132–134. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Tahrani AA, Ball A, Shepherd L, Rahim A, Jones AF and Bates A: The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK. Int J Clin Pract. 64:351–355. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL, Kramer AB, Gansevoort RT, van den Born J, Navis G and de Borst MH: Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis. PLoS One. 8:e558872013.PubMed/NCBI

30 

Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M and Vlahou A: Profilin 1 is a potential biomarker for bladder cancer aggressiveness. Mol Cell Proteomics. 11:M111.0094492012. View Article : Google Scholar

Related Articles

Journal Cover

2014-February
Volume 7 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tian X, Zhao L, Ge J, Zhang Y and Xu Y: Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy. Exp Ther Med 7: 411-416, 2014
APA
Tian, X., Zhao, L., Ge, J., Zhang, Y., & Xu, Y. (2014). Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy. Experimental and Therapeutic Medicine, 7, 411-416. https://doi.org/10.3892/etm.2013.1426
MLA
Tian, X., Zhao, L., Ge, J., Zhang, Y., Xu, Y."Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy". Experimental and Therapeutic Medicine 7.2 (2014): 411-416.
Chicago
Tian, X., Zhao, L., Ge, J., Zhang, Y., Xu, Y."Elevated urinary level of vitamin D‑binding protein as a novel biomarker for diabetic nephropathy". Experimental and Therapeutic Medicine 7, no. 2 (2014): 411-416. https://doi.org/10.3892/etm.2013.1426